Jzp-441
Payments companies reported to CMS as associated with Jzp-441. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jzp-441, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jzp-441
These are the largest totals companies reported as associated with Jzp-441. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Revati Shreeniwas | Stanford, CA | Pulmonary Disease | $374,200.00 |
| Rajesh Sharma | Jackson, MS | Neurology (Psychiatry & Neurology) | $138,300.00 |
| Marc Levin | Palo Alto, CA | Ophthalmology | $23,200.00 |
| Chirag Parikh | Baltimore, MD | Nephrology (Internal Medicine) | $18,750.00 |
| Philip Sager | San Francisco, CA | Cardiovascular Disease | $17,875.00 |
| William White | Farmington, CT | Hypertension Specialist | $4,050.00 |
Prescribed Jzp-441?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.